Picked for a well-established tolerability profile
As with all GnRH agonists, adverse events are related to hypo-estrogenism.2,3
A full list of adverse events is listed in the Prostap DCS summary of product characteristics
The information within this section of the website is intended for UK Healthcare Professionals. UK Practice Managers, patients prescribed Prostap DCS and members of the public should follow the relevant links:
As with all GnRH agonists, adverse events are related to hypo-estrogenism.2,3
A full list of adverse events is listed in the Prostap DCS summary of product characteristics
• In order to ensure adequate ovarian suppression in pre- and perimenopausal women, administer leuprorelin for at least 6-8 weeks prior to commencement of an aromatase inhibitor and on schedule without interruption throughout aromatase inhibitor treatment to avoid rebound increases in circulating estrogens in premenopausal women
• Following chemotherapy and before commencement of leuprorelin, confirm premenopausal status by blood concentrations of estradiol and FSH, to avoid unnecessary treatment in the event of chemotherapy-induced menopause
• Following commencement of leuprorelin and prior to aromatase inhibitor treatment, confirm ovarian suppression by assessment of circulating FSH and estradiol and repeat every 3 months during combination treatment
• Discontinue aromatase inhibitors within 1 month of the last Prostap SR DCS administration and within 3 months of the last Prostap 3 DCS administration
• Check relevant safety information of co-administered products
• Assess bone mineral density before starting treatment and monitor and treat for osteoporosis when appropriate
• Risk of musculoskeletal disorders when a GnRH agonist is used in combination with either an aromatase inhibitor or tamoxifen
• Hypertension has been reported. Monitor cardiovascular risk factors, blood pressure, hyperglycaemia and diabetes regularly in premenopausal women with breast cancer receiving GnRH in combination with exemestane or tamoxifen.
• Monitor patients with depression or depression history
• Patients should notify physician if regular menstruation persists
If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:
03333 000 181 medinfoemea@takeda.comIf you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:
020 3116 8000 enquiries@claritydtp.comIf you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below
Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 020 3116 8000.
You are now leaving Prostapdcs.co.uk. Takeda reviews the accuracy and content of its products that are available via the link you have selected. However, Takeda are not the owners of the website and as such do not control the overall running of the website or any non-Takeda-related content.
Please confirm if you wish to follow this link.
You are now leaving prostapdcs.co.uk. Takeda are the owners of the following website and control the overall running of the website and Takeda-related content.
Please confirm if you wish to follow this link.
You are now leaving Prostapdcs.co.uk. Takeda reviews the accuracy and content of its products that are available via the link you have selected. However, Takeda are not the owners of the website and as such do not control the overall running of the website or any non-Takeda-related content.
Please confirm if you wish to follow this link.
The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.
Please confirm if you wish to follow this link.
The table provides a worked example of the PA allowance calculation for a GP in a non-dispensing practice in England.
The dispensing fees and clawback rates are based on the smallest non-dispensing practice:
• Clawback rate: 3.17% represents total basic price per month £1-2,000
• Dispensing Fee: £2.405 represents total prescriptions calculated separately for each individual non-dispensing practitioner up to 449
Clawback rates and dispensing fees current as of October 2016, please refer to http://www.dispensingdoctor.org for the latest clawback rates and dispensing fees.